Memantine Chanelle (Memantine Hydrochloride)

Memantine is an NMDA‑receptor antagonist indicated for dementia‑related conditions.

• Alzheimer’s disease (moderate to severe): improves cognition, daily functioning and global clinical status.
• Dementia associated with Parkinson’s disease: may help maintain cognitive abilities and reduce functional decline.
• Behavioral symptoms of dementia (e.g., agitation): can lessen neuropsychiatric disturbances and improve patient comfort.

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission.

Memantine may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity, often resolves with continued use.
• Constipation: reduced bowel movements, may require dietary adjustment.
• Confusion: temporary disorientation, more frequent in elderly.
• Fatigue: feeling of tiredness or reduced energy.
• Hypertension: modest increase in blood pressure in some patients.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate medical attention.
• Seizures: rare occurrence, particularly in patients with a seizure history.
• Cardiac arrhythmias: irregular heart rhythms reported in isolated cases.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Severe hypotension: marked drop in blood pressure leading to dizziness or fainting.
• Neuroleptic malignant‑like syndrome: rare but life‑threatening condition.

Before initiating memantine therapy, consider the following safety measures.

• Renal impairment: assess kidney function and adjust dosing if necessary.
• History of seizures: monitor closely for increased seizure activity.
• Cardiovascular disease: observe blood pressure and heart rate regularly.
• Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity.
• Pregnancy and lactation: safety not established; weigh potential benefits against risks.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantine can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neurotoxic effects.
• Ketamine: additive blockade of NMDA receptors can exacerbate CNS depression.
• High‑dose zinc supplements: may reduce memantine absorption.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may worsen cognitive impairment.
• Diuretics: potential for orthostatic hypotension when used together.
• Central nervous system depressants (e.g., benzodiazepines): may enhance dizziness and sedation.